Low Peak Inspiratory Flow Rates are Common Among COPD Inpatients and are Associated with Increased Healthcare Resource Utilization: A Retrospective Cohort Study

References

• Kochanek KD, Xu J, Arias E. Mortality in the United States, 2019. NCHS Data Brief. 2020;(395):1–8.
   Google Scholar
• Press VG, Konetzka RT, White SR. Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program. Curr Opin Pulm Med. 2018;24(2):138–146. doi:10.1097/MCP.0000000000000454
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. 2021 report; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed July 20, 2021.
   Google Scholar
• Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857. doi:10.1016/j.rmed.2019.105857
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.1416
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate: an emerging biomarker in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(12):1577–1579. doi:10.1164/rccm.201901-0005LE
   PubMed Web of Science ®Google Scholar
• Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10(1):13. doi:10.1186/s40248-015-0012-5
   PubMedGoogle Scholar
• Grant AC, Walker R, Hamilton M, Garrill K. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015;28(6):474–485. doi:10.1089/jamp.2015.1223
   PubMed Web of Science ®Google Scholar
• Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14(3):309–315. doi:10.1089/089426801316970268
   PubMedGoogle Scholar
• Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26(11):2527–2533. doi:10.1185/03007995.2010.518916
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309–317. doi:10.1111/j.1742-1241.2011.02832.x
   PubMed Web of Science ®Google Scholar
• Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7(1):69–73. doi:10.1183/09031936.94.07010069
   PubMed Web of Science ®Google Scholar
• Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm. 1991;74:209–213. doi:10.1016/0378-5173(91)90239-K
   Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585–595. doi:10.2147/COPD.S195438
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Ward J, Gifford AH. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27(2):103–109. doi:10.1089/jamp.2013.1038
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Barnes CN, Moran EJ, Pendyala S, Crater GD. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis. 2019;6(4):321–331. doi:10.15326/jcopdf.6.4.2019.0137
   PubMed Web of Science ®Google Scholar
• Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217–224. doi:10.15326/jcopdf.4.3.2017.0183
   PubMed Web of Science ®Google Scholar
• Ohar JA, Loh CH, Lenoir KM, Wells BJ, Peters SP. A comprehensive care plan that reduces readmissions after acute exacerbations of COPD. Respir Med. 2018;141:20–25. doi:10.1016/j.rmed.2018.06.014
   PubMed Web of Science ®Google Scholar
• Pajewski NM, Lenoir K, Wells BJ, Williamson JD, Callahan KE. Frailty screening using the electronic health record within a medicare accountable care organization. J Gerontol A Biol Sci Med Sci. 2019;74(11):1771–1777. doi:10.1093/gerona/glz017
   PubMed Web of Science ®Google Scholar
• Butler DC, Petterson S, Phillips RL, Bazemore AW. Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery. Health Serv Res. 2013;48(2 Pt 1):539–559. doi:10.1111/j.1475-6773.2012.01449.x
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Yamamura Y, Ozeki T, Iga T, Yamada Y. Analysis of relationship between peak inspiratory flow rate and amount of drug delivered to lungs following inhalation of fluticasone propionate with a Diskhaler. Biol Pharm Bull. 2007;30(1):162–164. doi:10.1248/bpb.30.162
   PubMed Web of Science ®Google Scholar
• Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775–1782. doi:10.1016/S0140-6736(18)30668-8
   PubMed Web of Science ®Google Scholar
• Barnes CN, Mahler DA, Ohar JA, Lombardi DA, Crater GD. Peak inspiratory flows: defining repeatability limits and a predictive equation for different inhalers. Chest. 2020;158(4):1413–1419. doi:10.1016/j.chest.2020.03.072
   PubMed Web of Science ®Google Scholar
• Broeders ME, Molema J, Hop WC, Vermue NA, Folgering HT. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98(12):1173–1179. doi:10.1016/j.rmed.2004.04.010
   PubMed Web of Science ®Google Scholar
• Represas-Represas C, Aballe-Santos L, Fernández-García A, et al. Evaluation of suboptimal peak inspiratory flow in patients with stable COPD. J Clin Med. 2020;9(12):3949. doi:10.3390/jcm9123949
   PubMed Web of Science ®Google Scholar
• Ding N, Zhang W, Wang Z, et al. Prevalence and associated factors of suboptimal daily peak inspiratory flow and technique misuse of dry powder inhalers in outpatients with stable chronic airway diseases. Int J Chron Obstruct Pulmon Dis. 2021;16:1913–1924. doi:10.2147/COPD.S311178
   PubMed Web of Science ®Google Scholar
• Harb HS, Laz NI, Rabea H, Abdelrahim MEA. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients. Eur J Pharm Sci. 2020;147:105298. doi:10.1016/j.ejps.2020.105298
   PubMed Web of Science ®Google Scholar
• Duarte AG, Tung L, Zhang W, Hsu ES, Kuo YF, Sharma G. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstr Pulm Dis. 2019;6(3):246–255. doi:10.15326/jcopdf.6.3.2018.0163
   PubMed Web of Science ®Google Scholar
• Clark AR, Weers JG, Dhand R. The confusing world of dry powder inhalers: it is all about inspiratory pressures, not inspiratory flow rates. J Aerosol Med Pulm Drug Deliv. 2020;33(1):1–11. doi:10.1089/jamp.2019.1556
   PubMed Web of Science ®Google Scholar